CI-107

N/A

Report date: 2026/04/29 20:02:18

Base Information

Drug NameCI-107

Drug Alias NameCI107

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsAnti-CD3

TargetsEpidermal growth factor receptor erbB1T cell surface glycoprotein CD3

Therapy Area/IndicationsColonic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCytomx Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesCytomx Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsColonic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A